Moperone (Luvatren, since discontinued) is a typical antipsychotic of the butyrophenone class which is marketed in Japan for the treatment of schizophrenia. It is an antagonist for the D<sub>2</sub> (K<sub>i</sub> 0.7âÂÂ1.9 nM), D<sub>3</sub> (K<sub>i</sub> 0.1âÂÂ1 nM), and 5-HT<sub>2A</sub> (K<sub>i</sub> 52 nM) receptors. It also has a high binding affinity for the sigma receptors.